RESUMO

Nasal dilators were created to expand the nasal valve area. The aim of this systematic review was to verify physiological parameters associated to running performance with the use of nasal dilators. This study was registered in PROSPERO (CRD42021225795). According to the PICOS framework studies were included: Population: healthy subjects; Intervention: nasal dilators; Comparison: control group, placebo, minimal intervention, health education or other intervention; Outcomes: cardiorespiratory parameters and subjective perceptions; Study: randomized controlled trials, repeated measures or within-subjects design. The databases searched were MEDLINE, EMBASE, CENTRAL The Cochrane Library, CINAHL, SPORTDiscus, Web of Science, PEDro and Scopus. The descriptors "Running", "Nasal Dilator", "Randomized Controlled Trial", and synonyms were used. The risk of bias was assessed using the PEDro scale. Random effects Der Simonian and Laird model were used. The assessment of the certainty of the evidence was carried out using the GRADE approach. Eleven articles were included. There was a difference in favour of the nasal dilator when compared to placebo for maximal oxygen uptake and rating of perceived exertion. The certainty of the evidence was very low. Future studies will probably have an impact on estimation of the effect.

Assuntos

RESUMO

OBJECTIVE: Women with gynecologic cancer may suffer from pelvic floor dysfunction (PFD). Before radiotherapy, prehabilitation with pelvic floor muscle exercises (PFME) and vaginal dilator (VD) might prevent it and foster sexual life. This study aims to explore the experience of gynecologic cancer patients getting external beam radiation treatments regarding barriers to and facilitators of adherence to a prehabilitation program to prevent PFD. METHODS: This qualitative research with thematic content analysis included 11 women with gynecologic cancer and different levels of adherence to PFME and VD. Participants were interviewed based on a semi-structured script. The information was analyzed manually, assisted with Nvivo12® software, and triangulated with open coding. RESULTS: High self-motivation, desire to improve their health, symptoms of improvement, availability of time, the desire to resume sexual life, and the support of the partner were facilitators of adherence. The instructional exercise audio, clarity of the information, and closer communication with the physical therapist were also valued. The main barriers were general malaise secondary to oncological treatments, forgetfulness, lack of time, misinformation, lack of coordination with the treatment team, discomfort with the VD, and a feeling of shame. Feedback from the attending physician was a facilitator when present or a barrier when absent. CONCLUSION: These barriers and facilitators should be considered when designing and implementing preventive programs with PFME and VD. Behavioral counselling should consider the desire to remain sexually active; in such cases, including the partner in the therapeutic process is appraised. Otherwise, the focus should be on benefits for maintenance of pelvic floor function.

Assuntos

RESUMO

Overview: Hemorrhoidal disease (HD) is a common surgical disorder. The treatment modalities can be surgical or nonsurgical. Every surgical option has its own indications and limitations. Postsurgical symptomatic recurrence rates are low and vary between different techniques. The ideal way to deal with recurrent HD is not clear. Material and Methods: The present prospective case series enrolled a total of 87 patients (54male/33 female). Thirteen out of 87 patients (15%) had history of previous intervention for HD. Amodification of the standard technique was adopted for patients with recurrent HD. A mean follow-up of 22 months was achieved. Results: Stapled hemorrhoidectomy (SD)was performedin13patientswho had historyof previous surgical intervention for HD. There were no adverse events related to the technique. Patients with recurrent HD had severe pain scores with SH as compared to patients who underwent SH at the first time. There were no wound related complications. Conclusion: Stapled hemorrhoidectomy can be performed easily and offers good results in patients with recurrent HD. (AU)

Assuntos

RESUMO

BACKGROUND: Numerous studies have shown that the external nasal dilator (END) increases the cross sectional area of the nasal valve, thereby reducing nasal resistance, transnasal inspiratory pressure, stabilizing the lateral nasal vestibule, and preventing its collapse during final inhalation. OBJECTIVES: Our objective was to carry out a systematic review of the literature and meta-analysis on the effects of the END during physical exercise. METHODS: After selecting articles in the PubMed, Cochrane Library and EMBASE databases, 624 studies were identified. However, after applying the inclusion and exclusion criteria, 19 articles were considered eligible for review. RESULTS: Those studies included in the meta-analysis, the maximal oxygen uptake (VO2max.) outcome was assessed in 168 participants in which no statistically significant difference was found, MD (95% CI) = 0.86 [- 0.43, 2.15], p = 0.19, and I2 = 0%. The heart rate (HR) outcome was assessed in 138 participants in which no statistically significant difference was found, MD (95% CI) = 0.02 [- 3.19, 3.22], p = 0.99, and I2 = 0%. The rating of perceived exertion (RPE) outcome was assessed in 92 participants in which no statistically significant difference was found, MD (95% CI) = - 0.12 [- 0.52, 0.28], p = 0.56, and I2 = 27%. CONCLUSIONS: The external nasal dilator strip showed no improvement in VO2max., HR and RPE outcomes in healthy individuals during exercise.

Assuntos

RESUMO

BACKGROUND: the external nasal dilator (END) has been employed for the purpose of aiding sporting performance. The objective of this study was to evaluate nasal function and cardio-respiratory capacity in healthy adolescent athletes using the END. METHODS: double-blind, crossover clinical trial in which adolescents were evaluated while using the experimental and placebo END during physical exercise. Values for peak nasal inspiratory flow (PNIF), nasal resistance (NR) and maximal oxygen uptake (VO2max) were obtained in randomized order. Additionally, the rating of perceived exertion (RPE) after the cardio-respiratory test was assessed. RESULTS: for the 71 adolescents evaluated, the use of the experimental END, compared to the placebo, produced a significant improvement in values of PNIF (177.4 ± 20.9 L/min and 172.8 ± 20.2 L/min) (p = 0.020), NR (0.24 ± 0.16 and 0.27 ± 0.16) (p = 0.007), VO2max. (39.5 ± 5.2 mL/kg. min-1 and 37.5 ± 5.2 mL/kg. min-1) (p < 0.001) and RPE (6.0 ± 2.2 and 5.5 ± 2.4) (p < 0.001), respectively. CONCLUSION: the END reduced NR, increased PNIF and improved VO2max. In addition, it improved RPE after the maximal cardio-respiratory test. The use of the END can significantly improve nasal function, increase cardio-respiratory capacity and reduce rating of perceived exertion during a maximal test involving adolescent athletes.

Assuntos

RESUMO

OBJECTIVE: There are many predisposing factors associated with vaginismus, but there is lack of data in the literature regarding which and how of these factors influence the success rate of treatment. Our aim is to investigate the effects of factors that are considered as predisposing factors for vaginismus on treatment prognosis and success rate, with cognitive-behavioral therapy and desensitization exercises after sexual therapy. METHODS: Patients with vaginismus were divided into three groups. Group 1: patients who successfully completed vaginal penetration exercises after sexual therapy and experienced vaginal sexual intercourse; Group 2: patients who started penetration exercises but could not reach success; Group 3: patients who discontinued treatment before starting exercises. Demographic and sexual parameters were compared between the groups. RESULTS: There were statistically significant differences between the groups in terms of history of vaginismus in relatives (4.3%, 23% and 35.7%, p=0.047, respectively), the unsuccessful therapy history (69%, 61% and 21.4%, p=0.014, respectively), and anal and/or oral sex ratios (47.8%, 7.7% and 57.1%, p=0.019, respectively). Mean number of sessions were significantly higher in patients saying, "It is my fault" than among those perceiving it as a common problem (10.6±2.9 ve 7.5±5.7, p=0.042, respectively), and in patients with sexual disorder in their male partners than those not having any problem (13.3±3.7 ve 8.2±3.7, p=0.013, respectively). CONCLUSION: Patients are more resistant to treatment if they have a history of vaginismus among relatives or when one of the couple say, it is his or her fault.

Assuntos

RESUMO

OBJECTIVE: There are many predisposing factors associated with vaginismus, but there is lack of data in the literature regarding which and how of these factors influence the success rate of treatment. Our aim is to investigate the effects of factors that are considered as predisposing factors for vaginismus on treatment prognosis and success rate, with cognitive-behavioral therapy and desensitization exercises after sexual therapy. METHODS: Patients with vaginismus were divided into three groups. Group 1: patients who successfully completed vaginal penetration exercises after sexual therapy and experienced vaginal sexual intercourse; Group 2: patients who started penetration exercises but could not reach success; Group 3: patients who discontinued treatment before starting exercises. Demographic and sexual parameters were compared between the groups. RESULTS: There were statistically significant differences between the groups in terms of history of vaginismus in relatives (4.3%, 23% and 35.7%, p=0.047, respectively), the unsuccessful therapy history (69%, 61% and 21.4%, p=0.014, respectively), and anal and/or oral sex ratios (47.8%, 7.7% and 57.1%, p=0.019, respectively). Mean number of sessions were significantly higher in patients saying, "It is my fault" than among those perceiving it as a common problem (10.6±2.9 ve 7.5±5.7, p=0.042, respectively), and in patients with sexual disorder in their male partners than those not having any problem (13.3±3.7 ve 8.2±3.7, p=0.013, respectively). CONCLUSION: Patients are more resistant to treatment if they have a history of vaginismus among relatives or when one of the couple say, it is his or her fault.

RESUMO

Vaginal dilation, currently considered as the first-line therapy for vaginal aplasia in patients with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, is a safe and effective treatment that aims to create a functional neovagina. However, rigid vaginal dilators classically described in the literature usually cause physical discomfort and side effects that can lead to vaginal necrosis. Here, we present two cases of MRKH syndrome patients with vaginal agenesis whose main complaint was the inability to have sexual intercourse with their partners. Considering unavailability of acrylic dilators and previous studies reporting good responses with the use of silicone dilators in women with post-radiotherapy vaginal stenosis, the medical team and patients opted for creation of a neovagina through the daily use of silicone vaginal dilators. Patient 1 developed an 8-cm vagina after 6 months of treatment and had a satisfactory sex life with her partner. Patient 2 developed a 7-cm vagina and reported significant symptom improvement. None of the patients developed side effects after the treatment. The use of inexpensive and easily accessible silicone vaginal dilators may be an effective and noninvasive alternative with few side effects for women with vaginal agenesis, particularly in the developing countries.

Assuntos

RESUMO

STUDY OBJECTIVES: The aim of this study was to evaluate the effects of nasal dilator strip (NDS) as a placebo intervention compared with continuous positive airway pressure (CPAP) treatment in patients with severe obstructive sleep apnea (OSA). METHODS: Patients were treated with both NDS and nasal CPAP. The sequence was randomized and interposed by 15 days of washout. Polysomnography was performed at baseline and on the first night of intervention with NDS and CPAP (titration). The Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), and Beck Depression Inventory (BDI) were completed at baseline and at the end of both interventions. A questionnaire on the comfort and satisfaction (0 = no to 10 = total) was completed at the end of each intervention. RESULTS: Twenty-six patients with OSA were evaluated (19 male; age 46.3 ± 9.3 y; body mass index 33.2 ± 5.1 kg/m2; ESS 15.8 ± 4.1; apnea-hypopnea index 60.7 ± 25.2). Adherence was high in both NDS (98%) and CPAP interventions (94%; 5.8 ± 1.7 h/night). In contrast to the baseline values, NDS intervention had no significant effect on all polysomnographic parameters, but NDS improved somnolence (ESS 13.0 ± 5.4, p = 0.001) and depressive symptoms (BDI 7.7 ± 6.9, p = 0.005). Reported satisfaction was significantly higher for CPAP than for NDS (sleep quality 9.2 ± 0.8 vs. 6.1 ± 2.1; wake up at morning: 8.6 ± 1.2 vs. 6.0 ± 2.2; daily activities: 8.9 ± 1.4 vs. 5.8 ± 1.5; quality of life: 8.3 ± 2.1 vs. 3.8 ± 3.5, p < 0.001), but similar low levels of difficulty for both interventions were observed (1.3 ± 2.2 vs. 0.3 ± 1.3, p = 0.098). CONCLUSIONS: Our data indicate that NDS is an attractive placebo intervention for randomized controlled trials evaluating the effects of CPAP in sleepy patients with OSA.

Assuntos

RESUMO

Our goal was to revise the literature about external nasal dilators (ENDs) as to their definition, history, and current uses. We reviewed journals in the PubMed and MEDLINE databases. The current uses hereby presented and discussed are physical exercise, nasal congestion and sleep, snoring, pregnancy, cancer, and healthy individuals. Numerous studies have shown that ENDs increase the cross-sectional area of the nasal valve, reducing nasal resistance and transnasal inspiratory pressure and stabilizing the lateral nasal vestibule, avoiding its collapse during final inspiration. These effects also facilitate breathing and are beneficial to patients with nasal obstruction. Furthermore, END use is simple, noninvasive, painless, affordable, and bears minimum risk to the user. Most studies have limited sample size and are mainly focused on physical exercise. In conclusion, ENDs seem useful, so further studies involving potential effects on the performance of physical tests and improvements in sleep quality are necessary, especially in children and teenagers.

RESUMO

Introdução: O objetivo deste estudo é avaliar o uso do Dilatador Nasal Qiar®– Abridor Nasal e Levantador da Ponta Nasal, em pacientes com obstrução nasal e seus efeitos no ronco, apneia obstrutiva do sono, exercício físico, congestão nasal e respiração nasal. Métodos: Participaram do estudos 30 pacientes que responderam ao questionário da escala de sonolência Epworth, Índice de Qualidade de Sono de Pittsburgh, realizaram exame otorrinolaringológico completo, Rinometria Acústica e Polissonografia. Resultados: Polissonografias demonstraram diferenças significativas entre noite controle e noite de tratamento com Qiar®na eficiência, arquitetura e fragmentação do sono, tempo de ronco e Índice de apneias-hipopneias; Qiar® teve bom impacto no IAH, reduziu 50% do número de eventos respiratórios e em 64,1% o tempo de ronco. Testes de aptidão física demonstraram melhora significativa no tempo e VO2 máximo no grupo Qiar® (31,8 ml/kg/min), comparado ao controle (25,8 ml/kg/min). Houve significativo bem-estar usando Qiar®, 28 pacientes (93,3%) relataram ser melhor ou muito melhor sua respiração e desempenho no teste físico. Todos os resultados foram correlacionados com Rinometria, PSG e Teste de Aptidão Física. Conclusões: Este estudo demonstrou que Qiar® é eficaz na redução da obstrução nasal, roncos e apneia obstrutiva do sono, melhora da respiração durante exercícios físicos, diminuição da congestão nasal, facilita respiração pelo nariz, melhora arquitetura e qualidade do sono. Seu efeito é imediato, sem efeitos colaterais, com ação mecânica, sem medicamentos, pode ser recomendado como alternativas para descongestionantes e corticosteroides nasais tópicos e também para pacientes que não querem ou não podem fazer outros tipos de tratamentos.

Introduction: The aim of this study is to evaluate the use of Nasal Dilator Qiar®, a nasal opener and nasal tip lifter, in patients with nasal obstruction and its effect on snoring, obstructive sleep apnea, exercise, nasal congestion and nasal breathing. Methods:The study included 30 patients who answered the Epworth Sleepiness Scale and the Pittsburgh sleep quality index questionnaires, and underwent complete ENT examination, acoustic rhinometry and polysomnography (PSG). Results: PSG showed significant differences between control night and night with Qiar® treatment in the efficiency, architecture and fragmentation of sleep, time snoring and apnea-hypopnea index (AIH); Qiar® had good impact on the AHI, and it reduced the number of respiratory events by 50% and time snoring by 64.1%. Physical fitness tests demonstrated significant improvement in time and peak VO2 in the Qiar® group (31.8 ml/kg/min) as compared to the control group (25.8 ml/kg/min). There was significant well-being using Qiar®, as 28 patients (93.3%) reported better or much better breathing and physical performance. All results were correlated with Rhinometry, PSG and Physical Fitness Test. Conclusions: This study demonstrated that Qiar® is effective in reducing nasal obstruction, snoring and obstructive sleep apnea, improves breathing during exercise, reduces nasal congestion, eases breathing through the nose and improves the architecture and quality of sleep. Its effect is immediate, without side effects, with mechanical action, without medication, and it can be recommended as an alternative to decongestants and topical nasal corticosteroids and also for patients who do not want or cannot use other types of treatments.

Assuntos

RESUMO

OBJECTIVES: Evaluate the cardio-respiratory capacity (VO2max.) and peak nasal inspiratory flow (PNIF) of healthy adolescent athletes with experimental and placebo external nasal dilator strips (ENDS). METHODS: 48 healthy adolescent athletes between the ages of 11 and 15 were evaluated and submitted to a cardio-respiratory 1000 m race in randomized order. The participants had peak nasal inspiratory flow (PNIF) values measured using the In-check-inspiratory flow meter. Dyspnea intensity was evaluated after a 1000 m test race using a labeled visual analog scale for dyspnea. RESULTS: In relation to VO2max., when the participants used the experimental ENDS, significantly higher means were noted than when the placebo was used (53.0 ± 4.2 mL/kg min(-1) and 51.2 ± 5.5 mL/kg min(-1), respectively) (p<0.05). In relation to PNIF, there was a statistically significant difference between the experimental and placebo ENDS result, that being, 123 ± 38 L/min and 116 ± 38 L/min, respectively (p<0.05). The dyspnea perceived by the participants was representatively lesser in the experimental ENDS condition compared to the placebo after the cardio-respiratory test (p<0.05). CONCLUSIONS: The results suggest that the ENDS improve maximal oxygen uptake, nasal patency and respiratory effort in healthy adolescent athletes after submaximal exercise.

Assuntos

RESUMO

OBJECTIVES: The aim of the current study was to compare the objective and subjective effects of continuous positive airway pressure to the use of nasal dilator strips in patients with acromegaly and moderate to severe obstructive sleep apnea. METHODS: We studied 12 patients with acromegaly and moderate to severe obstructive sleep apnea (male/ females = 8/4, age = 52±8 ys, body mass index = 33.5±4.6 Kg/m², apnea-hypopnea index = 38±14 events/h) who had been included in a randomized, crossover study to receive three months of treatment with continuous positive airway pressure and nasal dilator strips. All patients were evaluated at study entry and at the end of each treatment by polysomnography, and Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index and treatment satisfaction questionnaires. ClinicalTrials.gov: NCT01265121 RESULTS: The apnea-hypopnea index values decreased significantly with continuous positive airway pressure treatment but did not change with the use of nasal dilator strips. All of the subjective symptoms improved with both treatments, but these improvements were significantly greater with continuous positive airway pressure than with the nasal dilator strips CONCLUSION: The use of nasal dilator strips had a much smaller effect on the severity of obstructive sleep apnea in patients with acromegaly and moderate to severe obstructive sleep apnea in comparison to the use of continuous positive airway pressure. Moreover, the improvement in several subjective parameters without any significant objective improvement in obstructive sleep apnea resulting from the use of nasal dilator strips is compatible with a placebo effect.

Assuntos